Rapport Therapeutics CEO Abraham Ceesay sells 8,210 common shares worth $328,018
RAPP•CEO sells shares under 10b5-1 plan
- Rapport Therapeutics CEO Abraham Ceesay sold 8,210 common shares on July 14, 2026 under a Rule 10b5-1 plan.
- Sales were priced at $39.72 and $40.57 per share, based on weighted averages.
- Direct common stock holdings fell to 539,817 shares.
Related News
Martin Marietta Materials Enters $1.5 Billion Three-Year Senior Unsecured Term Loan Facility On July 15, 2026 - SEC Filing
MLM•
Home BancShares Q2 FY26 revenue rises 10.6% to $295.1 million; net income climbs to $119.3 million
HOMB•
